WHO Pharmaceuticals Newsletter 2005, No. 03
(2005; 17 pages) Voir le document au format PDF
Table des matières
Ouvrir ce répertoire et afficher son contenuRegulatory Matters
Fermer ce répertoireSafety of Medicines
Afficher le documentAngiotensin converting enzyme (ACE)-Inhibitors - Continuing reports of angioedema
Afficher le documentAnticonvulsants - Drug-suicide link to be reviewed
Afficher le documentAyurvedic Medicines - Some contain high levels of heavy metals
Afficher le documentAntidepressants - Monitoring adults for suicidality
Afficher le documentAntidepressants - Use in children
Afficher le documentDextromethorphan - Abuse may be deadly
Afficher le documentFentanyl transdermal patches - Safety warnings regarding use
Afficher le documentFluorescein - Recommendations for safe use
Afficher le documentInterferon alfa-2b - Reports of osteonecrosis
Afficher le documentIsotretinoin - Update on reports of suicidal thoughts
Afficher le documentMifepristone and misoprostol - Reports of septic deaths
Afficher le documentNesiritide - Recommendations for appropriate use
Afficher le documentReboxetine - Genitourinary adverse effects
Afficher le documentStatins - Reports of peripheral neuropathy
Ouvrir ce répertoire et afficher son contenuMISCELLANY
 

Fentanyl transdermal patches - Safety warnings regarding use

USA. The FDA has issued a Public Health Advisory to alert patients and health-care providers to the dangers associated with fentanyl (Duragesic as well as generic preparations of fentanyl), and to provide recommendations on the safe use of the drug. The FDA reports that serious adverse effects, overdoses and death have occurred in patients using transdermal fentanyl patches for pain control, and that these cases are being investigated. The FDA highlights the following:

• Fentanyl patches are very strong opioid analgesics, and an overdose may be fatal. The patches should always be prescribed at the lowest dose needed.

• Fentanyl patches should not be used to treat short-term, postoperative or inconstant pain, and should only be used by opioid-tolerant patients who have chronic pain that is not well-controlled with shorter-acting analgesics.

• Patients using fentanyl patches and their caregivers should be advised to follow the directions for safe fentanyl use exactly.

• Patients using fentanyl patches and their caregivers should be advised that the patches should be stored in a safe place, out of children's reach, and that any used, defective or unneeded patches should be discarded safely by folding the sticky side of the patch together and flushing it down the toilet.

• Patients using fentanyl patches, their caregivers and prescribers should be aware of the signs of fentanyl overdose; if these occur, patients or their caregivers should seek medical attention immediately.

• Patients using fentanyl patches may experience a stronger effect or a sudden and potentially dangerous increase in fentanyl concentration if they are exposed to heat, have an increase in body temperature, use concomitant alcohol, or use drugs that affect fentanyl metabolism or affect brain function.


Reference:

FDA Public Health Advisory. United States Food and Drug Administration, 15 July 2005 (http://www.fda.gov).

 

vers la section précédente vers la section suivante
 

Dernière mise à jour: le 3 mai 2013